Abstract:Background Biological disease modifying antirheumatic drugs (bDMARDs) have been increasingly prescribed for RA in mainland China. Large scale epidemiological studies are needed to understand the treatment patterns and experience of bDMARD therapy in China. Objectives To characterize bDMARD therapy in Chinese RA patients in routine clinical practice. Methods Fifteen Chinese hospitals participated in this multi-center cross-sectional observational study. Consenting patients aged ≥18 years diagnosed with RA and receiving marketed bDMARDs were included. Results In total, 802 patients (81.3% women) met the inclusion criteria. The mean age (SD) was 49.0 (13.9) years. Analysis of available data of dosage and treatment duration of bDMARDs for all patients revealed that 66.6% patients were receiving ETN at a mean (SD) weekly dose of 38.2 (15.6) mg for 25.5 (47.0) weeks. The second most common bDMARD was tocilizumab administered to 17.0% patients at a mean weekly dose of 94.5 (21.9) mg for 4.7 (7.5) weeks. Only 7.5% and 6.6% patients were receiving adalimumab and infliximab, respectively. Using DAS28 score as the evaluation index, 32.8%, 42.2%, 12.4%, and 12.6% patients showed high, medium, low disease activity, and disease remission, respectively. Compared with patients (62.7%) receiving bDMARDs for <3 months, whose DAS28 score was 4.6 (1.5), those receiving bDMARDs for ≥3 months exhibited significantly lower DAS28 scores (P<0.0001). In particular, patients (14.6%) receiving bDMARDs for ≥12 months exhibited DAS28 scores of 3.2 (1.4). In total, 89.5% patients were receiving a combination of bDMARDs and cDMARDs whereas 10.5% patients were receiving bDMARD monotherapy. Among the 84 patients receiving bDMARD monotherapy, 75.0%, 10.7%, 9.5%, and 4.8% were receiving etanercept (ETN), infliximab, tocilizumab, and adalimumab respectively; for ETN, 8.3% and 66.7% patients were using original ETN (Enbrel®) and ETN biosimilar (Yi Sai Pu®), respectively. Patients receiving concomitant therapy exhibited significantly lower DAS28 than patients receiving bDMARD monotherapy (4.3 vs. 4.8, P=0.011). Reasons for discontinuing or switching bDMARDs varied. For patients (n=58) who had received the same bDMARDs previously, the main reasons for discontinuing the bDMARDs were improvement of disease condition (31%), financial burden (24.1%), and adverse reactions (13.8%). For patients (n=93) switching to different bDMARDs, the main reasons were unsatisfactory efficacy of the previous bDMARDs (58.1%), adverse reactions (14.0%), improvement of disease condition (10.8%), and financial burden (10.8%). Conclusions This is the first large scale multi-center study to characterize bDMARD therapy in China. Patients receiving bDMARDs ≥3 months showed significantly lower DAS28 scores than patients receiving bDMARDs <3 months, although the treatment target was not achieved within 12 months in routine practice. Currently, ETN and tocilizumab are the most commonly used bDMARDs in China, and the proportion of patients receiving bDMARD monotherapy is lower than that in European countries. These results suggest that bDMARD therapy in China can be improved in many aspects. Acknowledgements This study was sponsored by Shanghai Roche Pharmaceuticals Limited Disclosure of Interest None declared

The Current Status of Usage and Treatment Adherence of Etanercept in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Safety and Efficacy of Etanercept-Methotrexate Combination Therapy in Patients with Rhupus: an Observational Study of Non-glucocorticoid Treatment for Rheumatic Diseases

Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE

The Trend of Targeted Therapies in Chinese Patients With Ankylosing Spondylitis: Results From a Real-Life Survey

AB1194 Treatment of Rheumatoid Arthritis with Biological Dmards in China: A Multi-Center Cross-Sectional Study

Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial

FRI0196 Real-World Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study

Remission Assessment of Rheumatoid Arthritis in Daily Practice in China: a Cross-Sectional Observational Study.

Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study

The Usage of Biological DMARDs and Clinical Remission of Rheumatoid Arthritis in China: a Real-World Large Scale Study

A multi-center,double-blind,randomized,placebo-controlled study on the efficacy and safety of etanercept and methotrexate in the treatment of active rheumatoid arthritis

Efficacy and Safety of Adalimumab in Chinese Patients with Moderate-To-Severe Plaque Psoriasis: Results from A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study

Efficacy and Safety of a Novel Recombinant Human Tumor Necrosis Factor-Α Receptor Ⅱ : Fc Fusion Protein in Chinese Patients with Active Ankylosing Spondylitis: Results of a Randomized, Double-Blind,multicenter Trial

Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial

Association Between C-reactive Protein Gene Variant and Treatment Efficacy of Etanercept in Ankylosing Spondylitis Patients Receiving Hip Arthroplasty

Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study

Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding

AB0501 Adverse Events with Treatment Regimens of Rheumatoid Arthritis (RA) Reported by Patients Applying Smart System of Disease Management (SSDM) Mobiles Tools: a Cohort Study of Ra Patients in China

Utilization Pattern Of Etanercept And Its Cost Implications In Moderate To Severe Psoriasis In A Managed Care Population

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study